NNRTI (antiretroviral)
Efavirenz
Brand names: Sustiva
Adult dose
Dose: 600mg OD at bedtime
Route: Oral
Frequency: OD nocte
Clinical pearls
- Largely superseded by INSTI-based regimens in BHIVA guidelines
- Take at bedtime to reduce CNS side effects
- HLA-B*5701 not relevant for efavirenz; no allergy testing required
Contraindications
- Severe hepatic impairment
- Concurrent terfenadine, astemizole, cisapride, ergots, midazolam, triazolam, voriconazole, St John's wort
- Hypersensitivity
Side effects
- CNS effects (vivid dreams, dizziness, depression, suicidality)
- Rash including SJS/TEN
- Hepatotoxicity
- QT prolongation
- Hyperlipidaemia
- Gynaecomastia
Interactions
- Many CYP-mediated — methadone (withdrawal), warfarin, hormonal contraception (reduced efficacy), statins, voriconazole (avoid), rifampicin
Monitoring
- Viral load
- CD4
- LFTs
- Lipids
- Mental health
- Pregnancy planning
Reference: BNF; BHIVA HIV guidelines; EACS; SmPC; https://bnf.nice.org.uk/drugs/efavirenz/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023